Celltrion's Truxima becomes 1st Korean biosimilar to top US prescriptions

Celltrion’s blood cancer treatment Truxima has become the first Korean biosimilar to top its segment in the United States life sciences market and is now the most prescribed rituximab drug in the world’s largest pharmaceutical market, the company said Tuesday. According to life sciences market analytics firm IQVIA, Truxima, which was developed by Celltrion as a rituximab biosimilar, accounted for a 35.8 percent prescription share in the US as of February this year. The milestone came about six y

By The Korea Herald